查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1392038

Insulin Lispro市场：按Insulin Lispro产品类型、按适应症、按年龄层、按药物类别、按配销通路、按地区

Insulin Lispro Market, By Product Type of Insulin Lispro, By Indication, By Age Group, By Drug Class (Humalog, Admelog and Other brands), By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 173 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计2023年全球Insulin Lispro市场规模为73.2亿美元，预计2030年将达111.5亿美元，2023年至2030年复合年增长率为6.2%。

报告范围 报告详情
基准年 2022年 2023年市场规模 73.2亿美元
实绩资料 2018-2021 预测期 2023-2030
预测期复合年增长率 6.20% 2030年市场规模预测 111.5亿美元
图 1.Insulin Lispro全球市场占有率(%)（按地区），2023 年
赖脯胰岛素市场-IMG1

Insulin Lispro用于治疗需要胰岛素治疗的第 1 型糖尿病（身体不会产生胰岛素且无法控制血液中糖含量的疾病）。始终与其他类型的胰岛素一起使用，除非与外部胰岛素帮浦一起使用。Insulin Lispro注射产品也用于改善第 2 型糖尿病成人患者的血糖控制，这些患者仅对口服药物反应不佳。Insulin Lispro是一种类似胰岛素，与人类胰岛素的不同之处在于两个胺基酸序列：B-28 处的脯胺酸和 B-29 处的离胺酸。这种修饰可防止胰岛素形成二聚体和六聚体，这些二聚体和六聚体的活性低于单体胰岛素。Insulin Lispro给药后吸收迅速，2～4小时内达到峰值，并持续有效18～30小时。

市场动态：

近年来，全球Insulin Lispro市场显着成长，主要得益于糖尿病患者数量的增加以及胰岛素输送设备领域的技术进步。这一增长预计将得到政府措施的增加、患者对胰岛素需求的增加以及已开发国家有利的医疗报销政策等因素的进一步支持。由于久坐习惯和不健康饮食习惯等生活方式的改变，全球罹患糖尿病的人数不断增加。根据国际糖尿病联盟统计，2021年约有5.37亿成年人患有糖尿病，预计2030年这数字将增加至6.43亿，2045年将增加至7.84亿。肥胖率的增加和久坐的生活方式是糖尿病病例增加的主要原因。然而，胰岛素类似物製剂的高成本和生物相似药製剂的可用性对市场成长构成了挑战。从积极的一面来看，积极的政府配合措施和新兴市场医疗保健服务的改善正在为该市场的参与者创造利润丰厚的机会。类似胰岛素输送装置和製剂的开发也可能塑造未来的动态。

本研究的主要特点

  • 本报告对全球Insulin Lispro市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率（CAGR%）。
  • 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
  • 它根据公司亮点、产品系列、主要亮点、业绩和策略等参数，介绍了全球Insulin Lispro市场的主要企业。
  • 该报告的见解使行销人员和经营团队负责人就未来的产品发布、类型升级、市场扩张和行销策略做出明智的资讯。
  • 全球Insulin Lispro市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 透过用于分析全球Insulin Lispro市场的各种策略矩阵，将有助于相关人员做出决策。

目录

第一章 研究目的与假设

  • 研究目标
  • 假设
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
    • 促进因素
  • 糖尿病盛行率增加
    • 抑制因素
  • COVID-19感染疾病导致胰岛素需求减少
    • 机会
  • 新产品推出增加
  • 影响分析
  • 主要亮点
  • 监管场景
  • 产品发布/核准
  • PEST分析
  • 波特的分析
  • 併购场景

第 4 章Insulin Lispro市场 –冠状病毒(COVID-19) 大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第 5 章Insulin Lispro市场，Insulin Lispro产品类型划分，2018-2030 年

  • 赖脯Insulin Lispro预充笔
  • 赖脯Insulin Lispro溶液小瓶
  • Insulin Lispro溶液盒

第六章 赖Insulin Lispro市场，依适应症划分，2023-2030 年

  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病
  • 其他的

第 7 章 赖Insulin Lispro市场，依年龄层划分，2023-2030 年

  • 儿童患者
  • 成年患者
  • 老年患者

第 8 章 赖Insulin Lispro市场，依药物类别，2023-2030 年

  • Humalog（礼来公司）
  • Admelog（赛诺菲）
  • 其他品牌

第 9 章 赖Insulin Lispro市场，依配销通路，2023-2030

  • 医院药房
  • 零售药房
  • 线上药房

第10章赖Insulin Lispro市场，依地区，2023-2030

  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第十一章竞争形势

  • Eli Lilly and Company
  • Sanofi
  • Novo Nordisk A/S
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Hoffmann-La Roche Ltd.
  • AstraZeneca PLC
  • Johnson & Johnson Services, Inc.
  • Biocon Limited
  • Mylan NV
  • Boehringer Ingelheim International GmbH
  • Wockhardt Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Bioton SA
  • Gan & Lee Pharmaceuticals, Inc.
  • Ypsomed AG

第12章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI5719

The global insulin lispro market size is estimated to be valued at US$ 7.32 Bn in 2023, and is projected to reach US$ 11.15 Bn by 2030 at a CAGR of 6.2% from 2023 to 2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 7.32 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 6.20% 2030 Value Projection: US$ 11.15 Bn
Figure 1. Global Insulin Lispro Market Share (%), By Region, 2023
Insulin Lispro Market - IMG1

Insulin lispro is used to treat type 1 diabetes (a condition in which the body does not produce insulin and cannot control the amount of sugar in the blood) in people who need insulin therapy. It is always used with another type of insulin, unless it is being used with an external insulin pump. Insulin lispro injection products are also used to improve glycemic control in adults with type 2 diabetes who do not respond well to oral medications alone. Insulin lispro is an analog insulin that differs from human insulin with a change in the sequence of two amino acids, proline at B-28 and lysine at B-29. This change prevents insulin from forming dimers and hexamers, which have lower activity than monomeric insulin. Insulin lispro is rapidly absorbed following subcutaneous administration, reaching peak levels within 2-4 hours and remaining effective for 18-30 hours.

Market Dynamics:

The global insulin lispro market has grown significantly in recent years, primarily due to an increase in the number of people living with diabetes and technological advancements in the field of insulin delivery devices. This growth is further expected to be supported by factors such as increasing government initiatives to improve healthcare and rising patient demand for insulin, as well as favorable medical reimbursement policies in developed countries. Changing lifestyles, such as an increased adoption of sedentary habits and unhealthy diets, have resulted in an increased number of people developing diabetes globally. As per the International Diabetes Federation, approximately 537 Mn adults were living with diabetes in 2021, and this number is expected to rise to 643 Mn by 2030 and 784 Mn by 2045. The increasing obesity rates and sedentary lifestyles have significantly contributed to this rise in diabetes cases. However, the high costs of insulin analogs and the availability of biosimilar alternatives remain a challenge for market growth. On the positive side, favorable government initiatives and improved access to healthcare services in developing nations present lucrative opportunities for players operating in this market. Developments in analog insulin delivery devices and formulations will also likely shape the future dynamics.

Key features of the study:

  • This report provides in-depth analysis of the global insulin lispro market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global insulin lispro market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Merck & Co., Inc., Pfizer Inc., Hoffmann-La Roche Ltd., AstraZeneca PLC, Johnson & Johnson Services, Inc., Biocon Limited, Mylan N.V., Boehringer Ingelheim, International GmbH, Wockhardt Ltd., Lupin Pharmaceuticals, Inc., Bioton S.A., Gan & Lee Pharmaceuticals and Ypsomed AG
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global insulin lispro market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin lispro market

Detailed Segmentation:

  • By Product Type
    • Insulin Lipro pre-filled pen
    • Insulin lispro solution vials
    • Insulin lispro solution cartridge
  • By Indication
    • Type 1 Diabetes
    • Type 2 Diabetes
    • Gestational Diabetes
    • Others
  • By Age Group
    • Pediatric Patients
    • Adult Patients
    • Geriatric Patients
  • By Drug Class
    • Humalog (Eli Lilly and Company)
    • Admelog (Sanofi)
    • Other brands
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  • Company Profiles
    • Eli Lilly and Company
    • Sanofi
    • Novo Nordisk A/S
    • Merck & Co., Inc.
    • Pfizer Inc.
    • F.Hoffmann-La Roche Ltd.
    • AstraZeneca PLC
    • Johnson & Johnson Services, Inc.
    • Biocon Limited
    • Mylan N.V.
    • Boehringer Ingelheim International GmbH
    • Wockhardt Ltd.
    • Lupin Pharmaceuticals, Inc.
    • Bioton S.A.
    • Gan & Lee Pharmaceuticals
    • Ypsomed AG

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Insulin Lispro, By Product Type of Insulin Lispro
    • Market Insulin Lispro, By Indication
    • Market Insulin Lispro, By Age Group
    • Market Insulin Lispro, By Drug Class
    • Market Insulin Lispro, By Distribution Channel
    • Market Insulin Lispro, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Growing prevalence of diabetes
    • Restrains
  • Decline in demand for insulin during Covid-19 pandemic
    • Opportunities
  • Growing launch of new product
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Insulin Lispro Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Insulin Lispro Market , By Product Type of Insulin Lispro, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Insulin Lipro pre-filled pen
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
  • Insulin lispro solution vials
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
  • Insulin lispro solution cartridge
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)

6. Insulin Lispro Market , By Indication, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Type 1 Diabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
  • Type 2 Diabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
  • Gestational Diabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)

7. Insulin Lispro Market , By Age Group, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Paediatric Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
  • Adult Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
  • Geriatric Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)

8. Insulin Lispro Market , By Drug Class, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Humalog (Eli Lilly and Company)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
  • Admelog (Sanofi)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
  • Other Brands
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)

9. Insulin Lispro Market , By Distribution Channel, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)

10. Insulin Lispro Market , By Region, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Country, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Country 2023 -2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country 2023-2030,(US$ Bn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country 2023-2030,(US$ Bn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country 2023-2030,(US$ Bn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country 2023-2030,(US$ Bn)
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country 2023-2030,(US$ Bn)

11. Competitive Landscape

  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi
  • Novo Nordisk A/S
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Hoffmann-La Roche Ltd.
  • AstraZeneca PLC
  • Johnson & Johnson Services, Inc.
  • Biocon Limited
  • Mylan N.V.
  • Boehringer Ingelheim International GmbH
  • Wockhardt Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Bioton S.A.
  • Gan & Lee Pharmaceuticals, Inc.
  • Ypsomed AG
  • Analyst Views

12. Section

  • Research Methodology
  • About us